Mr. Liu is the Head of Strategy and M&A, General Manager of International Businesses for Xiwang Group. After Xiwang’s acquisition of Iovate Health Sciences Inc, Mr. Liu also took on the additional role as Chief Investment Officer and Board Secretary for Iovate Health Sciences Inc. Prior to joining Xiwang and Iovate, Mr. Liu was a senior banker in the Investment Banking division of HSBC, where he had worked in both London and New York. During his time at HSBC, Mr. Liu has worked on a significant number of complex cross-border transactions across Asia, Europe and the Americas, including Xiwang’s acquisition of Iovate. During Mr. Liu’s investment banking career, he has advised on mergers and acquisitions transactions totaling more than $100bn in value.
Mr. Liu is currently focused on new strategic investment opportunities for both Xiwang Group and Iovate.
He graduated Magma Cum Laude from the Stern School of Business at New York University with degrees in finance and marketing.
July 18, 2017
4:30 PM - 5:00 PM
For the supplement industry, the relationship between China and the United States, is built on a back-and-forth trade dynamic that used to be ingredients-out/product-in. Now it’s the money coming out of China and into global investment deals that could lead to the biggest changes. Chinese customers may be hungry for U.S. branded supplements, but Chinese … Continued